Merus N.V. (MRUS): Price and Financial Metrics

Merus N.V. (MRUS): $17.40

-0.16 (-0.91%)

POWR Rating

Component Grades













Add MRUS to Watchlist
Sign Up

Industry: Biotech



in industry


  • Value is the dimension where MRUS ranks best; there it ranks ahead of 62.76% of US stocks.
  • The strongest trend for MRUS is in Growth, which has been heading down over the past 177 days.
  • MRUS's current lowest rank is in the Momentum metric (where it is better than 4.75% of US stocks).

MRUS Stock Summary

  • With a price/sales ratio of 21.77, MERUS NV has a higher such ratio than 94.7% of stocks in our set.
  • With a year-over-year growth in debt of 259.21%, MERUS NV's debt growth rate surpasses 94.53% of about US stocks.
  • Revenue growth over the past 12 months for MERUS NV comes in at -15.32%, a number that bests merely 11.47% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to MRUS, based on their financial statements, market capitalization, and price volatility, are TSVT, HOWL, CARA, AFMD, and RGNX.
  • Visit MRUS's SEC page to see the company's official filings. To visit the company's web site, go to

MRUS Valuation Summary

  • MRUS's EV/EBIT ratio is -5.8; this is 187.88% lower than that of the median Healthcare stock.
  • Over the past 83 months, MRUS's price/sales ratio has gone down 43.9.

Below are key valuation metrics over time for MRUS.

Stock Date P/S P/B P/E EV/EBIT
MRUS 2023-03-24 21.8 3.7 -6.9 -5.8
MRUS 2023-03-23 21.5 3.6 -6.8 -5.7
MRUS 2023-03-22 21.4 3.6 -6.8 -5.7
MRUS 2023-03-21 22.7 3.8 -7.2 -6.1
MRUS 2023-03-20 22.1 3.7 -7.0 -5.9
MRUS 2023-03-17 22.8 3.8 -7.2 -6.1

MRUS Growth Metrics

    Its 3 year net cashflow from operations growth rate is now at -192.1%.
  • The 2 year revenue growth rate now stands at 80.97%.
  • Its 5 year revenue growth rate is now at 271.51%.
Over the past 15 months, MRUS's revenue has gone up $7,314,000.

The table below shows MRUS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 45.629 -150.985 -63.643
2022-06-30 52.717 -132.804 -53.881
2022-03-31 52.412 -125.367 -75.555
2021-12-31 49.107 -59.627 -66.816
2021-09-30 43.414 -52.365 -80.359
2021-06-30 38.315 -40.987 -88.581

MRUS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MRUS has a Quality Grade of D, ranking ahead of 21.68% of graded US stocks.
  • MRUS's asset turnover comes in at 0.127 -- ranking 244th of 682 Pharmaceutical Products stocks.
  • ACUR, ABBV, and KMPH are the stocks whose asset turnover ratios are most correlated with MRUS.

The table below shows MRUS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.127 1 -1.828
2021-06-30 0.125 1 -4.520
2021-03-31 0.120 1 -2.933
2020-12-31 0.132 1 -2.684
2020-09-30 0.122 1 -2.459
2020-06-30 0.124 1 -1.944

MRUS Price Target

For more insight on analysts targets of MRUS, see our MRUS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $30.71 Average Broker Recommendation 1.25 (Strong Buy)

MRUS Stock Price Chart Interactive Chart >

Price chart for MRUS

MRUS Price/Volume Stats

Current price $17.40 52-week high $30.81
Prev. close $17.56 52-week low $12.03
Day low $17.31 Volume 489,700
Day high $18.85 Avg. volume 251,370
50-day MA $17.76 Dividend yield N/A
200-day MA $19.76 Market Cap 805.92M

Merus N.V. (MRUS) Company Bio

Merus B.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. The company was founded in 2003 and is based in Utrecht, Netherlands.

MRUS Latest News Stream

Event/Time News Detail
Loading, please wait...

MRUS Latest Social Stream

Loading social stream, please wait...

View Full MRUS Social Stream

Latest MRUS News From Around the Web

Below are the latest news stories about MERUS NV that investors may wish to consider to help them evaluate MRUS as an investment opportunity.

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

Josh Enomoto on InvestorPlace | March 15, 2023

Merus Announces Petosemtamab in Previously Treated Head and Neck Squamous Cell Carcinoma Abstract Selected for Plenary Session Oral Presentation at the AACR Annual Meeting 2023

– Plenary session oral presentation: Monday, April 17, 2023, 10:15 a.m.-12:15 p.m. ET– Poster presentation on petosemtamab in advanced gastric/esophageal adenocarcinoma: Monday, April 17, 2023, 1:30-5:30 p.m. ET– Investor call on Monday, April 17, 2023 at 6:30 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibo

Yahoo | March 14, 2023

Merus Announces Publication of an Abstract on Preclinical Mechanism of Action of MCLA-129 Selected for Poster Presentation at the AACR Annual Meeting 2023

Poster presentation: Tuesday, April 18, 2023, 1:30-5:30 p.m. ETUTRECHT, The Netherlands and CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of an abstract highlighting the preclinical evaluation of the bispecific antibody MCLA-129 for poster presentation at the American Associat

Yahoo | March 14, 2023

We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Yahoo | March 14, 2023

Merus Announces Financial Results for the Fourth Quarter and Full Year 2022 and Provides Business Update

– Zenocutuzumab (Zeno) in NRG1+ cancer potential registrational path and timeline update planned for first half of 2023 – Petosemtamab clinical and regulatory update planned for first half of 2023 – MCLA-129 clinical update planned for second half of 2023 – Based on the Company’s current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus’ operations into second half 2025 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) --

Yahoo | February 28, 2023

Read More 'MRUS' Stories Here

MRUS Price Returns

1-mo -8.76%
3-mo 12.48%
6-mo -13.13%
1-year -34.39%
3-year 38.76%
5-year -6.10%
YTD 12.48%
2022 -51.35%
2021 81.40%
2020 24.50%
2019 0.57%
2018 -27.84%

Continue Researching MRUS

Want to see what other sources are saying about Merus NV's financials and stock price? Try the links below:

Merus NV (MRUS) Stock Price | Nasdaq
Merus NV (MRUS) Stock Quote, History and News - Yahoo Finance
Merus NV (MRUS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9118 seconds.